Literature DB >> 11687717

Safety of magnetic resonance contrast media.

V M Runge1.   

Abstract

Intravenous contrast media, specifically the gadolinium chelates, are well accepted for use in the clinical practice of magnetic resonance imaging. The gadolinium chelates are considered to be very safe and lack (in intravenous use) the nephrotoxicity found with iodinated contrast media. Minor adverse reactions, including nausea and hives, occur in a low percentage of cases. The four agents currently available in the United States cannot be differentiated on the basis of these adverse reactions. Severe anaphylactoid reactions are also known to occur with all agents, although these are uncommon. This review discusses the safety issues involved with intravenous administration of the gadolinium chelates and off-label use. The latter is common in clinical practice and permits broader application of these agents.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11687717     DOI: 10.1097/00002142-200108000-00007

Source DB:  PubMed          Journal:  Top Magn Reson Imaging        ISSN: 0899-3459


  17 in total

1.  Safety and Efficacy of A High Performance Graphene-Based Magnetic Resonance Imaging Contrast Agent for Renal Abnormalities.

Authors:  Shruti Kanakia; Jimmy Toussaint; Praveen Kukarni; Stephen Lee; Sayan Mullick Chowdhury; Slah Khan; Sandeep K Mallipattu; Kenneth R Shroyer; William Moore; Balaji Sitharaman
Journal:  Graphene Technol       Date:  2016-08-03

Review 2.  Nephrogenic systemic fibrosis: a concise review for cardiologists.

Authors:  Benjamin Y C Cheong; Raja Muthupillai
Journal:  Tex Heart Inst J       Date:  2010

Review 3.  Conventional or Gadolinium containing contrast media: the choice between acute renal failure or Nephrogenic Systemic Fibrosis?

Authors:  Alexander R Rosenkranz; Thomas Grobner; Gert J Mayer
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

4.  Spurious hypocalcemia after gadodiamide-enhanced magnetic resonance imaging: a case report and review of the literature.

Authors:  Christopher D Moore; Robert C Newman; James G Caridi
Journal:  Rev Urol       Date:  2006

5.  Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management.

Authors:  David Rampton; Joergen Folkersen; Steven Fishbane; Michael Hedenus; Stefanie Howaldt; Francesco Locatelli; Shalini Patni; Janos Szebeni; Guenter Weiss
Journal:  Haematologica       Date:  2014-11       Impact factor: 9.941

6.  Safety of gadodiamide mixed with a small quantity of iohexol in patients with impaired renal function undergoing coronary angiography.

Authors:  Cem Barcin; Hurkan Kursaklioglu; Atilla Iyisoy; Sedat Kose; Hasan Fehmi Tore; Ersoy Isik
Journal:  Heart Vessels       Date:  2006-05       Impact factor: 2.037

Review 7.  MR imaging of aortic coarctation.

Authors:  F Secchi; A Iozzelli; G D E Papini; A Aliprandi; G Di Leo; F Sardanelli
Journal:  Radiol Med       Date:  2009-05-14       Impact factor: 3.469

Review 8.  Nephrogenic systemic fibrosis: an emerging entity.

Authors:  Sandip K Saxena; Manjuri Sharma; Mital Patel; Dimitrios Oreopoulos
Journal:  Int Urol Nephrol       Date:  2008-04-17       Impact factor: 2.370

9.  Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglumine (MultiHance) in children.

Authors:  Guenther Schneider; Hellmut Schürholz; Miles A Kirchin; Arno Bücker; Peter Fries
Journal:  Pediatr Radiol       Date:  2012-11-24

10.  Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis.

Authors:  Thomas C Kwee; Robert M Kwee
Journal:  Eur Radiol       Date:  2008-10-17       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.